Advertisement
Research Article Free access | 10.1172/JCI117486
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Brackett, J. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Sims, H. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Steiner, R. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Nunge, M. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Zimmerman, E. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by deMartinville, B. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Rinaldo, P. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Slaugh, R. in: JCI | PubMed | Google Scholar
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Find articles by Strauss, A. in: JCI | PubMed | Google Scholar
Published October 1, 1994 - More info
Medium chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common known genetic disorder of fatty acid oxidation. Most (approximately 80%) cases are homozygous for a single mutation: A to G replacement at nucleotide 985 (A985G). MCAD deficiency typically presents in the second year of life as hypoketotic hypoglycemia associated with fasting and may progress to liver failure, coma, and death. Prompt diagnosis and management may prevent long-term sequelae. MCAD deficiency was verified by analysis of urinary acylglycine and serum acylcarnitine species from two neonates referred for diagnosis. Full-length cDNA and MCAD exon 7 and 11 genomic clones were prepared for sequence analysis. Normal and mutant cDNAs were expressed in bacteria, and enzymatic activity was assayed by the ferricenium hexaflurophosphate method. Four compound heterozygote individuals from two unrelated families with A985G on one allele and a novel G to A mutation at nucleotide 583 (G583A) as the second mutant allele presented with MCAD deficiency in the first week of life. The expressed G583A mutant protein lacks enzymatic activity. This novel mutation, G583A, is associated with severe MCAD deficiency causing hypoglycemia or sudden, unexpected neonatal death. This previously unrecognized phenotype of MCAD deficiency may contribute significantly to preventable infant deaths.
Images.